Evaluating Predictors of Immune-Related Adverse Events and Response to Checkpoint Inhibitors in Myeloid Malignancies.
Gesiotto QJ, Swoboda DM, Shallis RM, Al Ali N, Padron E, Kuykendall AT, Song J, Talati C, Sweet K, Lancet JE, Zeidan AM, Komrokji RS, Sallman DA.
Gesiotto QJ, et al. Among authors: sweet k.
Clin Lymphoma Myeloma Leuk. 2021 Jun;21(6):421-424.e2. doi: 10.1016/j.clml.2021.01.010. Epub 2021 Jan 20.
Clin Lymphoma Myeloma Leuk. 2021.
PMID: 33583730
No abstract available.